HK1031099A1 - Cd8 as an inhibitor of the cellular immune system - Google Patents

Cd8 as an inhibitor of the cellular immune system

Info

Publication number
HK1031099A1
HK1031099A1 HK01100646A HK01100646A HK1031099A1 HK 1031099 A1 HK1031099 A1 HK 1031099A1 HK 01100646 A HK01100646 A HK 01100646A HK 01100646 A HK01100646 A HK 01100646A HK 1031099 A1 HK1031099 A1 HK 1031099A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
immune system
cellular immune
ctl
activity
Prior art date
Application number
HK01100646A
Other languages
English (en)
Inventor
Bent Karsten Jakobsen
George Fu Gao
Ulrich Conrad Gerth
Andrew Kelvin Sewell
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of HK1031099A1 publication Critical patent/HK1031099A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK01100646A 1997-10-28 2001-01-29 Cd8 as an inhibitor of the cellular immune system HK1031099A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9722779.7A GB9722779D0 (en) 1997-10-28 1997-10-28 Human CD8 as an inhibitor of the cellular immune system
PCT/GB1998/003235 WO1999021576A1 (en) 1997-10-28 1998-10-28 Cd8 as an inhibitor of the cellular immune system

Publications (1)

Publication Number Publication Date
HK1031099A1 true HK1031099A1 (en) 2001-06-01

Family

ID=10821228

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100646A HK1031099A1 (en) 1997-10-28 2001-01-29 Cd8 as an inhibitor of the cellular immune system

Country Status (17)

Country Link
US (1) US20070191278A1 (da)
EP (1) EP1024822B1 (da)
JP (1) JP2001521005A (da)
KR (1) KR100585246B1 (da)
CN (1) CN1256147C (da)
AT (1) ATE215833T1 (da)
AU (1) AU752910B2 (da)
CA (1) CA2308463A1 (da)
DE (1) DE69804839T2 (da)
DK (1) DK1024822T3 (da)
ES (1) ES2175798T3 (da)
GB (1) GB9722779D0 (da)
HK (1) HK1031099A1 (da)
NO (1) NO20002148L (da)
NZ (1) NZ504240A (da)
PT (1) PT1024822E (da)
WO (1) WO1999021576A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929993D0 (en) * 1999-12-17 2000-02-09 Avidex Ltd Substances
GB0107628D0 (en) * 2001-03-27 2001-05-16 Avidex Ltd Substances
GB0114533D0 (en) * 2001-06-14 2001-08-08 Avidex Ltd Substances
GB0115071D0 (en) * 2001-06-20 2001-08-15 Avidex Ltd Substances
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
GB2398300A (en) * 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
CA2574802A1 (en) * 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
EP2342321B1 (en) 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
MX347078B (es) * 2010-12-09 2017-04-10 Univ Pennsylvania Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
WO2016149404A1 (en) 2015-03-16 2016-09-22 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
CN115109120A (zh) * 2016-04-04 2022-09-27 英蒂分子公司 Cd8-特异性捕获剂、组合物及使用和制备方法
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2050346A1 (en) * 1989-03-15 1990-09-16 Mark L. Tykocinski Cd8-based pharmaceuticals
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same

Also Published As

Publication number Publication date
AU752910B2 (en) 2002-10-03
EP1024822B1 (en) 2002-04-10
PT1024822E (pt) 2002-09-30
ATE215833T1 (de) 2002-04-15
CA2308463A1 (en) 1999-05-06
KR20010024570A (ko) 2001-03-26
AU9637498A (en) 1999-05-17
DE69804839T2 (de) 2002-10-10
NZ504240A (en) 2002-11-26
US20070191278A1 (en) 2007-08-16
CN1256147C (zh) 2006-05-17
ES2175798T3 (es) 2002-11-16
CN1283120A (zh) 2001-02-07
WO1999021576A1 (en) 1999-05-06
GB9722779D0 (en) 1997-12-24
KR100585246B1 (ko) 2006-06-01
JP2001521005A (ja) 2001-11-06
NO20002148L (no) 2000-06-27
EP1024822A1 (en) 2000-08-09
DK1024822T3 (da) 2002-08-05
NO20002148D0 (no) 2000-04-27
DE69804839D1 (de) 2002-05-16

Similar Documents

Publication Publication Date Title
HK1031099A1 (en) Cd8 as an inhibitor of the cellular immune system
MX9707431A (es) Inhibidores de la proteina cinasa c.
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
DK0603251T3 (da) 1-substituerede 1H-imidazol(4,5-c)quinolin-4-aminer, mellemprodukter og farmaceutiske sammensætninger
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
FR2697252B1 (fr) Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
EA199700135A1 (ru) Ингибиторы клеточной адгезии
AU4048989A (en) Alkoxy-4(1h)-pyridone derivatives, processes for preparing them and their use as drugs
ES8606286A1 (es) Procedimiento para preparar nuevos derivados de benzazocinona y de benzazoninona
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
MX9701820A (es) Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.
AU6921300A (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
MY143570A (en) Compounds useful for inhibition of farnesyl protein transferase
AU1767297A (en) Benzo(C)quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors
EP0684831A4 (en) ALLOGENIC VACCINE AND METHOD FOR SYNTHESIZING THE SAME.
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
BG104452A (en) New derivatives of the methylenebisphosphonic acid
IL136225A0 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
ZA976754B (en) Novel tricyclic N-cyanoimines useful as inhibitors of farnesyl-protein transferase.
NZ503559A (en) Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081028